Galecto, Inc. (NASDAQ:GLTO) Short Interest Update

Galecto, Inc. (NASDAQ:GLTO – Get Rating) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 59,500 shares, a decrease of 35.0% from the March 15th total of 91,500 shares. Based on an average daily trading volume, of 76,900 shares, the short-interest ratio is presently 0.8 days. Currently, 0.6% of the shares of the stock are short sold.

Shares of Galecto stock traded down $0.25 during trading on Monday, reaching $2.26. The company’s stock had a trading volume of 66 shares, compared to its average volume of 75,594. The firm has a 50-day simple moving average of $2.17. Galecto has a 52-week low of $1.67 and a 52-week high of $16.41.

Separately, Zacks Investment Research raised shares of Galecto from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Tuesday, March 1st.

In related news, insider Bertil Lindmark purchased 14,604 shares of the firm’s stock in a transaction dated Tuesday, March 22nd. The shares were purchased at an average price of $2.16 per share, with a total value of $31,544.64. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 8.10% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in GLTO. Bank of America Corp DE boosted its position in Galecto by 617.3% during the 2nd quarter. Bank of America Corp DE now owns 35,490 shares of the company’s stock valued at $180,000 after buying an additional 30,542 shares during the period. Wells Fargo & Company MN boosted its position in Galecto by 118,463.2% during the 2nd quarter. Wells Fargo & Company MN now owns 45,054 shares of the company’s stock valued at $228,000 after buying an additional 45,016 shares during the period. Marquette Asset Management LLC bought a new position in Galecto in the 3rd quarter worth $87,000. Renaissance Technologies LLC raised its holdings in Galecto by 159.2% in the 3rd quarter. Renaissance Technologies LLC now owns 102,900 shares of the company’s stock worth $369,000 after purchasing an additional 63,200 shares in the last quarter. Finally, Millennium Management LLC bought a new position in Galecto in the 3rd quarter worth $299,000. 41.19% of the stock is owned by institutional investors and hedge funds.

Galecto Company Profile (Get Rating)

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung.

See Also